ADCT - Earnings call transcript Q3 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to the ADC Therapeutics Third Quarter 2021 Financial Results Conference Call. My name is Kevin, and I'll be your operator for today's call. At tthis time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. [Operator Instructions]

the to turn Relations Hamilton, now Manager. will call Amanda over Investor I begin. you Amanda, may

Amanda Hamilton

release operator. you, announcing financial update. press ADCT quarter release we under ir.adctherapeutics.com our XXXX on the This website business at and section. Thank results morning, third This issued release available the is a press

and Chief quarter Chief will Jenn and Creel, financial Financial Officer, Chris On Jennifer opening for Chief Officer; today's Martin, the call, third Commercial questions. Medical Herron, recent review business results before highlights discuss Officer; XXXX Executive Officer; our Joe Camardo, call Chief

contain As risks a reminder, forward-looking this statements. uncertainties. statements conference to call subject may are Such and

Such we and to as to conference titled filed the section to earlier by you Statement U.S. Securities and additional concerning those on to Regarding or required obligation implied forward-looking from we Cautionary of update For law. Exhibit in Forward-Looking this applicable Commission so report could statements, cause or Exchange date our factors undertaking differ forward-looking these only XX.X refer statements materially Form statements today. call, actual of disclaim results statements the any the expressed unless information Statements these X-K that do speak expressly in and with of

accordance or non-IFRS isolation includes IFRS. as should as financial a be non-IFRS for, financial measures with also presentation in measures substitute Today's information and and to, considered These measures. have in prepared not limitations in the addition

reconciliations earnings the historical to refer for should non-IFRS You the and measures. in IFRS third information to of financial comparable release company's contained definitional information the quarter measures

CEO, Chris the pass to over Martin. pleasure our my to now is It Chris? call

Christopher Martin

launch, quarter. I'm the goals. the everyone, to R&D and development for Thanks of an several successfully key the on pleased achieving pipeline Amanda, very our third executed our ZYNLONTA corporate driving share progress objectives and joining important us advancing update you, today. during We thank

date, accomplished what encouraged We launch ZYNLONTA delivering quarter net sales and are are launch. have months six approximately in we we $XX.X in first to now by million the our into the of

launch the need in team third-line-plus the significant experienced behind our and momentum good medical driven generated sales highly product profile, the of execution professionals. unique have by the of DLBCL strong and We unmet

Commercial a later details refractory share our in many by more provide this Void Officer little remain expanding footprint will possible FDA our relapsed approval, our ZYNLONTA or launch our as Chief to call. on with worldwide Herron, to Jennifer committed to patients as geographic we DLBCL. first

progress Joint our a application drug as received made also EMA tremendous bridging marketing initiation intended is of study in the Phase pivotal Venture authorization we and with orphan Overland The regulatory filing serve designation in China, China. The to the ADCT validated Europe. for which in basis X

to agents line geographic in in a and we earlier expansion, agent as single continuing evaluate DLBCL In in with to ZYNLONTA are addition other follicular combination also in opportunities lymphoma.

of On to which into KAAGX the value driving the the targeting R&D are for NCI Phase initiated study targeting advance our pipeline development programs, a DLK-X. for and the front, with ADCT-XXX we We continue for ADCT-XXX collaboration entered X the company. for long-term important

programs trial refractory Medical Chief For Camardo, Cami, will the relapse study Phase on Hodgkin we Officer Xb the elaborate and Joe our solid continue moments. X our Phase to tumors. a in advance in key few Lymphoma in

Healthcare by ZYNLONTA million of commercialization Finally, development of our for financing Royalty $XXX entering for continued into cash runway Cami. the during the to we quarter, with up a Partners extended and agreement the

on provide I with some ZYNLONTA like to launch. over our insights Jennifer now to to call Jennifer? turn would progress the the

Jennifer Herron

an you, ZYNLONTA on update today launch. to and morning here Thank U.S. happy Chris, good be everyone. share I'm the to

the ZYNLONTA representing of our sales. million, first full report We net pleased sales ZYNLONTA quarter quarter $XX.X to third in are of

medical unmet driven affairs professionals. by been the medical marketing, of significant DLBCL and and in our access need seasoned performance early This sales team strong has market cross-functional differentiated profile, of third-line-plus launch execution the ZYNLONTA's product

additional volume prioritized and from accounts dynamics, accounts accounts, team launch new of CI existing including into progress increased In NCCN terms key our insight our centers. and commercial has our driving good and made initiating

our Despite prescribe in continuing we launch terms efforts of COVID-related competing share have significant of also voice. are challenges, targeted and perception in intent awareness, resulted in brand to increases and well

differentiated both with to The community-based resonate ZYNLONTA continues physicians. product academic and profile

total equal third from academia academic of greater center ordering support proportion XX% accounts the volume the of quarter surprisingly and community. an not in QX During than resulted coming with

become as Recently, we turnaround and have payer seen increasing reimbursement the community expected reliable. access as more volume from

we of patient our pleased progress. with very are access terms In

J-code Our for accelerate payer access and to barriers And with expect no thus and medical in broad local permanent we January the trial XXXX reimbursement, adoption. teams patients community have of encountered far. achieved

hear supports experience, which DLBCL that broad the we in experience to patient trial Anecdotally, the is of world similar population. the the real ZYNLONTA across third-line-plus LOTIS-X the patient use

in predominantly that the used patient therapy population, treatment with been ZYNLONTA including XX%. to Recall T been has investigator ZYNLONTA the in setting has also use go third-line who in trial, ORR received after of may XX patients T CAR patients initial fourth-line directed ZYNLONTA. our after with the LOTIS-X on an assessed While CAR CDXX

and and a days a combination single potential The of setting, is effect to Standard profile, every generally believe convenient ZYNLONTA differentiated of to days, the third-line-plus third-line-plus manageable respond be XX has in XX-minute product why competitive agent makes XX profile we time the side to an the that agent with which infusion median robust unique ZYNLONTA Care. a efficacy incredibly

impacts proactively and year, patient scheduling for variability face-to-face we around launch for visits be monitoring of with holiday opportunities season. the the upcoming As outlook the rest for the the the of COVID, the will

team operating depending including preferences. marketing, virtually guidelines have hybrid or to the affairs in agility regarding sales, engage COVID cross-functional navigating the geographic environment, person in access medical with launch the and market and Specifically, on the been both physician

hoped, we other about our and face-to-face months of as engagement interactions. not institutions half our have the all opened of at over had stable quickly While has up face-to-face been last few opportunities as

we the to recognizing incredibly encouraged profile ZYNLONTA's launch HCP summary, environment. the are In reception while positive momentum product date, dynamic in differentiated by to resulting generated

uncertainties the associated And evolution unlock updated team as benefit may indication. ZYNLONTA treatment. look an of of but opportunity progress. ZYNLONTA believe our the keeping We acknowledge the potential launch to in there pandemic, patient of the Standard remains focused its you on We who on label full is to our any the Care with to bringing from forward

Joe update Now, to the to pipeline. call I'll turn on Joe? an our provide over

Joe Camardo

in Jennifer. agents of in is ZYNLONTA with non-Hodgkin move treatment Lymphoma. in working very different Thank with earlier able ADC to am subtypes Therapeutics about to beyond combination be and how other you, lines to to first indication I studies today pleased you talk of our

relapsed for refractory the or diffuse lymphoma. we with LOTIS-X B-cell combination large trial, Starting mantle evaluating with the ZYNLONTA cell in are or ibrutinib

are ZYNLONTA administration as a Phase as to use durability and program We combination treatment. with initiating the the lines of well higher of potential of complete rate response of X more tolerability a in and earlier determine frequent dose response, for this

expect transplant. This to and end patients for this this Our the clinical supplemental trial trial ZYNLONTA refractory continues Phase in not patients year. ongoing of X eligible therapy BLA a cell intended to a confirmatory combination trial of second-line LOTIS-X is as who of or for with to filing DLBCL are we lead-in the complete by safety relapse stem enrollment of rituximab support enroll

duration relapsed and in a response published showed patients is XX was trial LOTIS-X of X Phase from patients X or data response median our of had showed refractory that ZYNLONTA response. including the The Phase that collicular Phase complete XX nine trial. a reached ongoing, in lymphoma study not X The to who

to we the of ZYNLONTA dose arms. additional with trials of combination combinations in In finding trials, the including these the by In in addition untreated that ZYNLONTA initiate study a of And to patients. previously R-CHOP aim different several DLBCL four year, study separate evaluates ZYNLONTA end

of the for conference. And These into new of ZYNLONTA, forward trials data ASH released we're explore upcoming be lines will across at non-Hodgkin therapy ZYNLONTA the lymphomas. discussing expansion finally, to b-cell looking to earlier

Moving to Cami.

in February, lymphomas plan the submission. lymphoma preliminary XXXX, With solid Phase for which the advance X in we a regulatory after have both XXXX we tumor our pathway next will steps trial to and half to continue Hodgkin Hodgkin of programs. in We first to completed and enrollment results the share

advance that tumors. leverages pipeline Cami trial our advanced in with with Phase ADC with ongoing supporting dose validated in are to escalation pembrolizumab Xb applied continue our patients of we our combination to solid also solid treatment We platform tumors. Furthermore, the

first-in-class the During in KAAGX, unmet X with quarter, treatment and triple medical negative first of the breast cancer ovarian resistant the solid including patient for study third candidate ADCT-XXX tumors we Phase patients cancer. platinum advanced of novel with a high need dose targeting the

prostate, breast, is AXL many ADCT-XXX, cancers. as uzoptirine, in promising Another pancreas, esophageal lung, such AXL. candidate is solid mipasetamab glioma pipeline over tumors expressed and targeting

to tumors We in in the the Xb this more of and combination Phase look program study solid the half in months. first expect forward details sharing XXXX about coming initiate to multiple we

As medical paraganglioma, unmet cancer. includes and to into lung earlier, need. collaboration carcinoma, This with DLKX with high the ADCT-XXX National neuroblastoma cell we Institute Chris develop Cancer a neuroendocrine mentioned in entered malignancies adrenocortical pheochromocytoma, targeting small

refractory X And a for or Hope to Anderson collaboration City with Phase acute relapse continues lymphoblastic of This finally, Medical our in X, leukemia. M.D. Centers. ADCT-XXX program in trial and is enroll CDXX patients targeting

updated of forward a to these we pipeline all robust R&D look with seven programs. development We also pre-clinical have programs you and keeping on

to Jen a I to that, turn With over financial give the call will update.

Jennifer Creel

Thank morning everyone. you, and Joe, good

in reported of million first release the As sales quarter press full were net $XX.X reflecting ZYNLONTA ZYNLONTA sales. earlier the today third quarter issued

XXth, as $XXX XXth year. June cash million September we to of of of as had of equivalents and compared As $XXX cash million this

the $XX used During operating roughly for in activities. third we cash million quarter

into clinical ZYNLONTA XXXX. and primarily $XXX $XXX $XX was for with entered expenses in third of expansion million, of portfolio. XXXX ZYNLONTA to were support agreement million for gross The of same the broad Royalty Healthcare including our to up quarter compared proceeds increase upon received $XX Partners we to affairs August, the million medical of In financing quarter R&D program launch for million the and closing. the the the a related

quarter and expenses the reflects of compared for The ZYNLONTA commercial XXXX. same to efforts. increase ongoing Selling marketing the launch quarter and million the and $X were million the expenses the marketing third in XXXX $XX for selling of for

due the G&A to of primarily of million public staged to quarter increase million commercial third the company. was The expenses a for to compared for same the needs increased $XX quarter support $XX of headcount XXXX. XXXX were

same XXXX to a $XX loss $XX quarter Net loss the million for compared the third of million was of XXXX. for quarter of net

loss Our the XXXX. per a same of in third loss of net quarter diluted share to quarter compared net the of XXXX $X.XX $X.XX was for

million $XX items that agreement quarter net the adjusted associated expense and Partners effective expense compensation a net for share-based quarter to the associated XXXX, with $XX third with adjusted loan royalty the measure Finally, Healthcare loss in compared an excludes Royalty convertible loss, was same financing interest the certain Deerfield XXXX. million of with of

loss increase same was investment clinical $X.XX The in adjusted loss our driven for ZYNLONTA adjusted a per the the for the the quarter to and by of in launch net diluted compared was in share net programs. primarily loss The XXXX. $X.XX quarter

will back for remarks. I Chris that, to call closing turn With the Chris?

Christopher Martin

you Jen, execute and to continued launch this Jennifer. a advance quarter has to conclude, Thank productive To been R&D and we on pipeline. Joe ZYNLONTA our ADCT. for

look on our Our quarters. launch updating XXXX are business. progress in objectives to the our on and we the We the execute coming to into aspects advancing year the of are of pipeline all remainder clear and the for of well-positioned and forward

for I'm pleased open questions. the call Operator? to now

Operator

you. Thank

We will answer question [Operator now session. the Instructions]. begin and

Stanley. comes Our Matthew question Morgan Harrison with first from

Matthew Harrison

Thanks Great. me. questions. morning. two guess I from for the Good taking

regulators you're to take? the just if that? to secondly, being or the once data going one see the duration any outline seen changes you're commercial quarter-over-quarter again in you in you of need other exactly sort Cami, of on you've I seeing commented I around So anything sources repeat or or you first the half terms And any maybe like steps to you've of wondering need prescribers on the then XX-XX was do XXXX meet are academic. know items can on Thanks. of business what launch. with where

Christopher Martin

Jennifer, first the the want take to you, Thank Joe, you second? do Matthew. question,

Joe Camardo

Sure.

Jennifer Herron

Hi.

good, Sounds Thanks. Chris. Hey, Matthew.

to I recent terms So greater evolution getting will and in community we academia. say would from what we're our of that over we're continue of increasing the in as quarter-over-quarter, seeing the the a most -- I and volume see weeks months in we percentage mentioned that use to expect coming continue.

So, and perspective community is I we're repeat predominantly coming from academia, but order weeks. recent still from a coming newer getting in think the volume the from accounts newer the

is, what into patient-by-patients we're the [ph] from we're early really their in approach hearing launch, to very it's months individualized looking I perspective, for a from six where a treatment say setting in perspective. getting is HCPs on I mean, that duration too a that From they're think third-line-plus patient depends what duration paradigm.

really hard a to general So it's population. to extrapolate

for it's think too that just I right early now.

Joe Camardo

Joe. Okay. This We'll a pretty follow standard is procedure.

study. part Here put has study, which in a standard. meeting pretty what a data, the compile a feeling don't to together well a meeting. book, do they as for next years we'll meeting few have questions said And latter we're possibilities The a FDA in sometime the we as case in last for answered approval request this accelerated the often of going with the that's a is a I year. them need have of confirmatory and the to finish and next, want a briefing proposal explain submission

Operator

Thank you.

comes Bank America. Our from with of Ahmad question next Tazeen

Tazeen Ahmad

afternoon. my Morning and for I'll you. Thanks questions. good with taking start

Matthew's maybe to on question first about ___. follow-up The

observations? a your I HL, a us on to in be far? the community the so expect more Thank for that then to just it doctors in doctor as of use can the had GBS you users? observation growth increased to of new follow-ups. are you. ZYNLONTA is then would secondly, what it prescribing refractory give based been setting from Or community relates with And it sense could whether limiting relapsed talks Cami, experience are rate where couple you So, any see you getting has feedback And mind or have more who've patients? And in

Christopher Martin

Tazeen. Thank Jennifer, want one, do the Again, to the second. first and take you Joe you,

Jennifer Herron

I repeat of and orders healthy mix repeat week accounts addition Community, and we're accounts. the you. thank new of and We're we're new adding from Tazeen, a think Yes. accounts seeing really the orders existing orders. every seeing new

in that concentration not not the your business. question? Is was it's a seeing I'm So community, of

Joe Camardo

risk based about had the question in We've of first the Okay. the increase GBS no With the the thing is regard now the balance over Cami, that benefit to seeing data is trial. on we're of incidence favorable.

in who treatments activities what relapsed prior who we're after median in including to treatment. and six that We pembrolizumab place mitigating that treating sure scientist and some also cell mind have particular keep failed with patients call be I have a rituximab stem have that make they of can and modern decide treatment patients patients who

a complete XX%. we've a of the So bar reached very with high there's and that response in rate range

the and we're next confident do we're FDA as to on which that positive we're see we able So, benefit that risk year. as will the long data to provide plan all

Tazeen Ahmad

to Okay. But to are you've that just made significant a [Indiscernible]? even you level of GPS changes expecting level the see with

Joe Camardo

And expect Could a be going think higher. Could have clinical to number seven lower practice. we number to We a now. we into cases the see. we've that be been of I expect able lot cases. be serious the go to we mitigate a to sorry. more is going I have X%, I that's that And And as the But number. And bit that's -- little cases. GPS when patients little X%, of the be mentioned

that rate and So, be complete we is given XX% that have think have a treatments to six patients and the demonstrate able physicians. repeatedly explain the the which side-effect that of is a to failed. addressable to in who This data here, an benefit we have it prior range, median response that

Tazeen Ahmad

Okay. Thank you.

Joe Camardo

Okay.

welcome. You're

Tazeen Ahmad

are currently just to can this looking as Lastly, see And relates patients? data mentioned year? we KAAGX just And into of for? are next for efficacy moving it what starting you. to level you Thank a remind you for other clinic options what platinum-resistant the Should expect year. ovarian, that the study specifically us any the then

Joe Camardo

a question asking can't Yes. sorry, -- I'm I have hear very KAAG? well. your Were you I about

Tazeen Ahmad

Yes.

Joe Camardo

Or about KAAG here.

Christopher Martin

treatment? to Joe, yes, expect of stage KAAGX, alternative see year? level And to sorry, you of patients this were this quick expect And -- data with question ovarian see? for sure. for was are what the therapies The cancer there any activity do we would what the

Joe Camardo

thanks. okay, Well,

thanks we that. hear hear products I which about. wanted everything So except our to I didn't heard Chris. of

share. data a advance we and according the We generally dose cancers. to to on escalation pace, going exactly year can not just refractory careful Phase in patients with the proceeding any we're have mean, right KAAG, at with we is how X safety this depending schedule. So it's started to our regular I which proceeds,

to So I'm year thinking maybe the proceed. some next we and data sometime in the a latter part plan could of develop have on safety

alternatives the it to The relapse. there serious aren't and Ovarian cancer is short really that is any reaches why answer is refractory once to of KAAG question a late continues ovarian a cancer option illness be highly attractive which stage here.

So, there of other that. normal now are is which is but development, KAAG in at novel, interesting maybe ovarian is on expression this KAAG. not the as novel why And there limited. that other is products nothing this right chose of there tumors, field pretty point are but options we But

Tazeen Ahmad

you. Thank Okay.

Joe Camardo

You're welcome.

Christopher Martin

[Indiscernible] but any tumor setting GBS in haven't solid Cami. with the we seen

Tazeen Ahmad

Yes.

you. Thank Okay.

Operator

Peaker from Our Coven. next from question Boris comes

Boris Peaker

Oh, on is at great. should question Can you we My be first see comment to ASH? expecting data ZYNLONTA. on the

Christopher Martin

be as Well, the you're about will it's tell to specific done, follow-up. I have longer data still But we I term see can't embargo. ASH, under going at that commonly you will because

subgroup have analyses. will We some

some same time. our -- recall of other have this in going patients we the not that you we at we're ZYNLONTA on have eligible trials As trial for the

reporting kinds the now other ASH to it longer And so been those follow-up. of going available we submitted also we're some conference. products And in do to and have analysis be on to addition have that

Boris Peaker

top-line anticipate also And data for data timing LOTIS-X what from readouts of you the do Got LOTIS-X, you is it. when can the and -- those?

Joe Camardo

LOTIS-X for That's about right. to be have data some determine year. that. But this started have time But really the next data. can't of tell the you it the be not we'll will LOTIS-X. we I likely how amendment probably won't completed part amendment -- proceeds from just by We XXXX. some when it will We're Yes. before

we're asked randomized Just LOTIS-X, the at part when just start of the the you point We'll we're about lead-in. finishing where this.

to and expect trial. it's XX then months event-driven remind We to take that XX just you I'll an

the So difference progression. rituximab/GemOx depends that and the we'll predicting the will determine of ZYNLONTA/rituximab on have between when events occurrence

I But XX So the it's period make said, tell is prediction. to to XX what enrollment I be going probably like you months. hard a can to

Boris Peaker

my taking for much very you Thank question. Great.

Joe Camardo

You're welcome.

Operator

Brian Cheng Our from next comes Cantor question with Fitzgerald.

Brian Cheng

team. It tracking well great and of congratulations historical one my you some more the of you're Thanks. against Thanks trajectory product quarter. on seems call have competitive And market taking on sense then I have DLBCLs. DLBCL? share in a you stand that the follow-up. Hey, a Do for sales for third-line-plus in where

Christopher Martin

Jennifer.

Jennifer Herron

Yes. Yes. Thanks, Brian. the Thanks for question.

We performance. this are quarter's pleased with

of of terms In my holding in own in awareness in I share familiarity terms remarks increases prescribe. made metrics, to we've We're voice. some significant mentioned and also and as intent our

So with we're happy that.

the local change our again And We are to market QX better monitoring but require. on conditions terms we can plan a months. the competitive. we quite that into COVID, as The hybrid that get make of winter remain that could sure is closely we launch in as the looking adapt dime

of effects pharmacists of things seasonal are differentiated face-to-face course, going with we patient is about the QX interactions, of be in the the to engaging visits. of nurses, ZYNLONTA any because of of of carefully and and profile that first kind terms our importance this One is physicians watching

to you So, quarter that updating yes, about we'll looking as optimistic cautiously we're wraps. be forward and QX

Brian Cheng

think your patient is their thoughts Maybe And CTOS just How And the set and selection of Can update what AXL meeting potential from the and at we program. of an indications? front? manufacturing read-through ahead your this us the you on update then, Jennifer. competitor targeted to initial on on AXL give latest targeted your the Great, Sarcoma about program? you. the update XXX ADC should from Thank later month. the upcoming XXX

Christopher Martin

[ph] normally the site side manufacturing I Phase program. product. we're know, now X conjugation we're we product. lyophilized the We you using Brian, frozen do did the the And manufacturing AXL study in on moving think to as specific dose as using escalation significance

that the of first supply year. half is underway address I'll the well for to clinical we hand So the will to Joe? to Joe in clinical aspects. start manufacturing over study next the

Joe Camardo

Okay. Chris. Thanks

better an interested our that target. yet. find hear a You doing and to would details working Sarcoma tumor -- surprised won't be those respond and with AXL. a we how out of investigators also us we're have to working there attractive to likely finalized than selecting to little We're lot why do don't To couple get of and sarcoma FDA try our a some have more determine in populations with reasons But AXL. we protocol of to a to the of are try just can been literature-based

to probably plan. So able protocol some don't final year. to final the first the have have share I'll happen the when I details just of going share, half be we data. to next current but That's then that in That's

And competitor, we but the from try a to we that think regard can competitors, high again, very I what to PBD learn our tend with toxin. here. we to And we potency unique have I can't -- have

think with the enhance does into entry to trial tumor. on a now. to the toxin going expression potency that we able and able levels proposal malignant get be expressed that our that toxin to in we're depend to I highly determine -- So help of the cells. ability it think be we'll it's That's of the the finding our of And the really AXL chances the

and year. So give there's I'll now able on half be we're the a couple this doing first of but in, be it more details in next filled you to to of

Brian Cheng

We Thanks look that. to for my forward taking Great. question.

Joe Camardo

you. Thank

Operator

Kelly Shi with comes next question Jefferies. Our from

Kelly Shi

my for question. on you taking the Congrats quarter. great Thank

mentioned as we to change? QX. So ZYNLONTA. staying at to have follow-up expect going net Cami. gross Are I'll And on the some to the Is same it in XX% around for

Christopher Martin

Jennifer?

Jennifer Creel

there. I is Hey, jump Chris. in can Jenn. This

Christopher Martin

please Of in. jump course, Jenn

Jennifer Creel

for Jenn, Jennifer, question. Thanks Kelly the confusing.

the specific and some an patient we this net, we right net can that's our this of X-K we we'd at a see it's range general kind for in gross the population. We our have estimates this gross fluctuate. expect deductions. to So sales months But right deductions actuals to early in in and still morning. the infusion this XX% days few to included details do really QX expect only around that you in have really filed were of drug our And But point.

we'll updates. there's continue the and if Thanks question. any let forward move So, for to we as this monitor

Kelly Shi

Thank you. of association share Cami, could the some And prior think treatment with incidence also you talks PD-X for possible the you hypothesis GBS. [ph]. Do GBS regarding antibody has the

PD-X have also seen learned? trigger will happen the what this cases some be possibility We solid will based documented treatment for GBS have in you able you. to heavily And tumors pro-treated patients. rule out on Thank to

Christopher Martin

Joe, do to you want take that?

Joe Camardo

very have first of bit patients Hodgkin all, a of embere predisposition It's that we know Sure. good to lymphoma more the a [ph]. question. a And

all system we exactly the that's the to checkpoint specifically know immune do of in know At from point find can immuno-inflammatory immune yet. it's speculative not to right enhancement when against with consider be our side inconsistent that It's that minds that the related that to have effects So this nervous don't And happen. we of inhibitors now, for we can't keep But us. we some activates data that trigger it the one has just system. kind kinds thing this. these to of We system.

Cami activity. immune the system. cannot go. of specific a about reasonable as We the we as about activation the or hypothesis that far So That's say unique can it's anything

even We've look that as this in tumor that's just what's confidence now for look to of we're mentioned of have actually solid trying actually on as and to continuing happening saw pretty solid getting patients And in many happen on I the to comparative a well not that and you're solid tumor the when patients And checkpoint we this. with incubators. we're based the And question. are we a the done very saw it's lymphoma. solid the high work the we this into really lymphoma Hodgkin program. for Hodgkin early something in enough to -- tumors, of the help a observation difficult how embere level welcome a into predisposition tumor have this patients. Hodgkin in that is lymphoma to regard patients people with it's to Thanks With program this. the with But lot - will

Kelly Shi

the so the color. last Thank regarding for you much AXL program. One if made question I

and not be So from able of some design competitors the like on response, able show but maybe expression between to that wonder expectation or actually tumor able be to. you'll biomarker your on Therapeutics I are comment front? clinical some actual to study some correlation would the what's programs ADC

Christopher Martin

really can't we as finalized not be the commentary it's listed design, I clinical on because give finalize clintontrials.gov. you But Yes. any once yet. the do on this protocol will

like hear never about So it's not you'll it.

looking how a are one the That's cell. toxin get as You a the out is that over thing is AXL looking at door certainly actual We're will. that bit our to is driving companies But into different. point at for tumor. pursuing AXL how to expression a way to little determine they're response,

really the toxin AXL. activity looking be may there a depress of to is antibody some getting highly potent cell. Now, But of we're activity the into our what at

not as -- specific data see in into you'll it's comparison very mechanisms. just it is really look the cell And AXL more at driving target the to our future. malignant it's different are a as toxin look to a as And totally getting cell good so way a at the of AXL

Okay.

Kelly Shi

Okay. That's very helpful. Thank you.

Christopher Martin

You're welcome.

Operator

with comes Capital question RBC from McKay next Markets. Kennen Our

Kennen McKay

CME had and I Very on three commercial Alright. Thanks the for taking questions the here. there. quarter. impressive on congrats result question

that and when solid just how and data of of it's a we effect have trial with associated Cami might GBS to congrats can to then could you the the a models? lastly, FDA tumors And requested you risk wanted in meeting combo that wanted had going on or just question history see And biomarkers? are Have identified see Cami? GBS. or replicated treatment to for any animal And with was being and I expect First, factors pembro clarify pre-BLA and another etiology then the any Thanks recurrence, again. that from whether second, trial?

Christopher Martin

questions. Three Okay.

to regard FDA the with all of First request.

we when We We one-year request meeting the have will X for been Then Phase we request of a duration follow-up proceeded median. duration data The have to with still showing was agreed the And important a considered them just before send meeting. duration we that be on wait and showing The the a that not not a meeting we'll an these for not data reached We've still compile our yet with yet. the one-year in reason response still reached we so program been compiled we has February follow-up the to variable, one-year requested reminder, we and the in in that XXXX. good data response. of is want follow-up would patients. the we data response be median until of data. the the don't

So going that's But until wait to on thing. your good we're a follow-up.

from can't you it's my speculating and it's like maybe Because knowledge to question, Second animals we But a activities have We syndrome. a model replicate to animals. in T-Rex this really just of really replicate Guillain-Barré replicate this in animal model an I'm be we some have cells. of then tumor animal here, transplant Hodgkin phenomenon lymphoma we in with you that when a happen long can you that's way actual immuno-inflammatory an the can model. can't the depress

yielded histories. a It history? the great a looking. is a these we're how it's but because And exactly far reminder, specific there treatment yet treatment -- complicated so biomarker? what still which a hasn't what And at very asked, we us, are looking Is suggest, answer you you for about about question are

we're a So It's it's surprise you continuing look. not big can't out something. obvious, not sort but something that to

mitigate like rate with side kinds have promising do these target a try there's patients. this, on right the what given to such you're to effect of in we that to research So response

program is the escalation. That the as in do is Cami I And reflects But finish, we know, the very in when to you solid tumors I need we're that that are thing, drugs And third we're well. studying. can't still dose new to got because exactly the you've going tumors solid you carefully. think tell proceeding for high doing

able be we chosen of and pembro once we've terms we're to dose the So making combination we'll responses What what getting. we we're learned safety. that what kind sure and show in of Cami get we've of right then with expand

So it's of bit enrollment. well very in still uncertain, a proceeding but little terms

I Did everybody. Okay. lose

Operator

I'm At over Chris. not further the any back questions. to And I'd time like Okay. to this call showing turn

Christopher Martin

today. for keeping very forward you Thank you call to Bye. And the a everyone updated Thank day. our We on have joining progress. look much you. nice

Operator

Ladies and conclude presentation. gentlemen, this today's does

a You wonderful day. disconnect have may and now

ADC Therapeutics (ADCT) 2 Nov 212021 Q3 Earnings call transcript